Systemic Juvenile Idiopathic Arthritis (SJIA)
Also known as: Systemic Juvenile Idiopathic Arthritis / SJIA / Systemic onset juvenile idiopathic arthritis / Still's disease NOS / Systemic onset juvenile chronic arthritis (disorder) / Still's disease / Still's disease -RETIRED- / Juvenile-Onset Still Disease / Polyarticular juvenile rheumatoid arthritis (disorder) [Ambiguous] / Juvenile rheumatoid arthritis &/or Still's disease / Still's disease - juvenile rheumatoid arthritis (disorder)
Drug | Drug Name | Drug Description |
---|---|---|
DB00026 | Anakinra | A recombinant form of human interleukin-1 receptor antagonist used in the treatment of rheumatoid arthritis, neonatal-onset multisystem inflammatory disease and deficiency of interleukin-1 receptor antagonist (DIRA). |
DB06168 | Canakinumab | An interleukin-1β blocker used to treat Periodic Fever Syndromes such as Cryopyrin-Associated Periodic Syndromes (CAPS) and Familial Mediterranean Fever (FMF), and also to treat active Systemic Juvenile Idiopathic Arthritis (SJIA). |
DB06273 | Tocilizumab | An interleukin-6 (IL-6) receptor antagonist used to treat Cytokine Release Syndrome (CRS), Systemic Juvenile Idiopathic Arthritis (sJIA), Giant Cell Arteritis (GCA), and Rheumatoid Arthritis (RA). |
Drug | Drug Name | Target | Type |
---|---|---|---|
DB00026 | Anakinra | Interleukin-1 receptor type 1 | target |
DB06168 | Canakinumab | Interleukin-1 beta | target |
DB06273 | Tocilizumab | Interleukin-6 receptor subunit alpha | target |
DB06273 | Tocilizumab | Cytochrome P450 3A4 | enzyme |
Drug | Drug Name | Phase | Status | Count |
---|---|---|---|---|
DB06372 | Rilonacept | 1 | Completed | 1 |
DB00087 | Alemtuzumab | 2 | Recruiting | 1 |
DB01073 | Fludarabine | 2 | Recruiting | 1 |
DB01005 | Hydroxyurea | 2 | Recruiting | 1 |
DB01042 | Melphalan | 2 | Recruiting | 1 |
DB04572 | Thiotepa | 2 | Recruiting | 1 |
DB11817 | Baricitinib | 3 | Recruiting | 1 |
DB06168 | Canakinumab | 3 | Completed | 4 |
DB06168 | Canakinumab | 3 | Terminated | 1 |
DB06168 | Canakinumab | 3 | Withdrawn | 1 |
DB06273 | Tocilizumab | 3 | Completed | 3 |